Cronos Group Inc. (CRON)
NASDAQ • Healthcare
September 22, 2026 at 19:42 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Cronos Group Inc. keeps $45 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 44 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Cronos Group's revenue topped consensus in the second fiscal quarter of 2026, with results reported on Aug. 6 showing about $70.6 million in revenue versus roughly $43.0 million expected, a 64.4% beat, and revenue was up 111% from $33.5 million a year ago. Gross profit came in at about $28.5 million, with gross margin near 40%, while operating cash flow was about $18.8 million. Consensus for the next period calls for EPS of $0.01 on revenue of $55.1 million.
About Cronos Group Inc.
Cronos Group Inc. is a NASDAQ-listed healthcare company that develops cannabinoid products for therapeutic and recreational use, spanning cannabis cultivation, production, and commercialization. In FY2025, the company recorded $193.4 million in revenue. Its portfolio ranges from hemp-derived wellness and beauty products to dried cannabis formats, oils, and extracts sold under consumer brands.
Today's Snapshot
CRON is 3% higher at 3.43, close to its 52-week high of 3.61. Cronos Group saw revenue accelerate in 2026.
Trading Volume
Below 10d avg (741.1K)
662.2K
vs S&P 500 Today
Outperforming Market
+2.95%
Updated: September 22, 2026 at 19:32 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$2.83 - $3.31Buy
- RSI (14)63.88Neutral
- Stochastic %K (14, 3, 3)82.93Sell
- MACD Level (12, 26)0.06Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.